Shanghai OPM Biosciences (688293.SH) is planning a major asset restructuring, and trading will be halted starting tomorrow.
Aupuma (688293.SH) issued an announcement that the company is planning to purchase... by issuing shares and paying cash.
Shanghai OPM Biosciences (688293.SH) announced that the company is planning to acquire the controlling rights of Pengli Biomedical Technology (Shanghai) Co., Ltd. ("Pengli Biomedical") through the issuance of shares and cash payment, while also raising funds. The transaction is expected to constitute a major asset restructuring. The company's stock is scheduled to be suspended from trading starting on January 17, 2025 (Friday), with the suspension expected to last for no more than 5 trading days.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
